neoepitope - OmicsDI

Show results for

Unknown (243)
Genomics (46)
Proteomics (20)
Transcriptomics (14)
Genomic (1)
Clinical (1)
Other (1)

Organisms

Andropogon gerardi (16)
Bacteria (16)
Canis lupus familiaris (16)
Cnidaria (16)
Cricetulus griseus (16)
Eukaryota (16)
Fasciola (16)
Hepatitis B virus (16)
Human alphaherpesvirus 1 strain 17 (16)
Human betaherpesvirus 5 (16)
Madurella mycetomatis (16)
Mesocricetus auratus (16)
Miscanthus x giganteus (16)
Mus musculus (16)
Orthoflavivirus (16)
Panicum virgatum (16)
Platyhelminthes (16)
Pseudomonas aeruginosa AES-1R (16)
Rattus norvegicus (16)
Rattus rattus (16)
Rhodococcus jostii RHA1 (16)
Saccharomyces cerevisiae (16)
Severe acute respiratory syndrome coronavirus 2 (16)
Sorghastrum nutans (16)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (16)
Streptococcus pneumoniae (16)
Streptomyces coelicolor A3(2) (16)
Toxoplasma gondii (16)
Homo sapiens (15)
Mus musculus (9)

Organisms

Homo sapiens (13)
Mus musculus (10)
Mus musculus musculus (1)

Repository

ENA (38)
geo (16)
pride (16)
EGA (5)
MassIVE (4)
biostudies-arrayexpress (1)
dbGaP (1)
EVA (1)

Tissue

Cell culture (5)
Lung (3)
B cell (2)
Colon (2)
Epithelial cell (2)
Adenocarcinoma cell line (1)
Blood (1)
Cell line cell (1)
Cell suspension culture (1)
Epithelial cell of lung (1)
Epithelial cell of skin gland (1)
Lung cancer cell line (1)
Melanoma cell line (1)
Ovary (1)
Pancreatic cancer cell line (1)
Primary cell (1)
Skin (1)
T cell (1)

Disease

Colon cancer (2)
Lung adenocarcinoma (2)
Lymphoma (2)
Melanoma (2)
Squamous Cell Carcinoma of Head and Neck (1)
Adenocarcinoma (1)
Cell type cancer (1)
Lung cancer (1)
Melanomatosis (1)
Osteoarthritis (1)
Ovarian carcinoma (1)
Pancreatic cancer (1)

Technology Type

Mass Spectrometry (16)
Shotgun proteomics (7)
Data-dependent acquisition (4)
Affinity purification coupled with mass spectrometry proteomics (3)
Bottom-up proteomics (3)
Data-independent acquisition (3)
ILLUMINA, Illumina HiSeq 2500, NextSeq 500, Nanostring (1)
Immunopeptidomics (1)
SRM/MRM (1)

Instrument Platform

Orbitrap Fusion Lumos (4)
Illumina MiSeq (1)
- (1)
Orbitrap Eclipse (1)
Q Exactive HF (1)
TimsTOF Pro 2 (1)

Publication Date

2026 (8)
2025 (7)
2021 (6)
2024 (5)
2019 (3)
2023 (2)
2022 (2)
2020 (2)
2017 (1)
2018 (1)

First Public Date

2024 (7)
2026 (6)
2022 (4)
2021 (4)
2020 (4)
2019 (4)
2025 (3)
2023 (3)
2017 (3)

Study status

Active, not recruiting (1)

Study type

DNA-seq (1)
Interventional (1)

Release Date

2021 (38)
2023 (33)
2022 (33)
2025 (26)
2018 (22)
2020 (18)
2019 (18)
2024 (16)
2017 (11)
2016 (7)
2026 (4)
2015 (4)
2014 (2)
2012 (2)
2009 (2)
2008 (2)
2010 (1)
2006 (1)
2005 (1)
2004 (1)
2000 (1)
1999 (1)

Lab affiliation

Charité-University Medicine Berlin (1)
Cleveland Clinic, Lerner Research Institutute, Biomedical engineering, Cleveland, Ohio (1)
Core Unit Proteomics, Berlin Institute of Health at Charité-Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany (1)
Department of Immunology, Interfaculty Institute for Cell Biology, University of Tübingen, Tübingen, Germany (1)
Department of Peptide-based Immunotherapy (1)
Department of clinical chemistry, Institute of Biomedicine, The Sahlgrenska Academy at Gothenburg University (1)
German Cancer Reseach Center (DKFZ) (1)
Head of research group Quantitative and Systems Biology; Max Planck Institute for Biophysical Chemistry; Goettingen; Germany (1)
INCLIVA Biomedical Research Institute (1)
Molecular Medicine Partnership Unit (MMPU), Heidelberg University & European Molecular Biology Laboratory (EMBL) Department of Pediatric Oncology, Hematology and Immunology, Heidelberg University & Hopp Children’s Cancer Center, National Center for Tumor Diseases (NCT) (1)
NKI Proteomics Facility (1)
Netherlands Cancer Institute Proteomics Facility (1)
Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892 (1)
Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA 7Present address: Bristol Myers Squibb, Lawrenceville, NJ 08901, USA and Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA. (1)
Translational Control and Metabolism, German Cancer Research Center (DKFZ), Heidelberg, Germany (1)
Weizmann Institute of Science (1)

Location

United States (1)

Previous page
1 / 33
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 33
Next page

Sort by:

Relevance

Page size

Impact of HLA aberrations on tumor neoepitope presentation

PRJNA1426023 | ENA

Impact of HLA aberrations on tumor neoepitope presentation

PRJNA1426022 | ENA

Reversion analysis reveals the immunogenicity in vivo of a poorly MHC I-binding cancer neoepitope

A mutation that results in tumor rejection activity in a neoepitope (which is a poor binder of Kd) influences the immunogenicity of the tumor as a whole. Our results demonstrate the activity in vivo of a poorly-MHC I-binding cancer neoepitope.

ORGANISM(S): Mus musculus

2021-05-31 | GSE171100 | GEO

Reversion analysis reveals the immunogenicity in vivo of a poorly MHC I-binding cancer neoepitope

PRJNA718324 | ENA

NeoGuider: neoepitope prediction using advanced feature engineering.

Not available

S-EPMC12838086 | biostudies-literature

The neoepitope landscape in pediatric cancers.

Not available

S-EPMC5577668 | biostudies-literature

Structural dissimilarity from self drives neoepitope escape from immune tolerance.

Not available